Molecure aims to discover and develop drugs that have novel mechanisms of action to address inflammation, fibrosis and oncology. The company’s two lead assets, OATD-01 (a chitotriosidase inhibitor) and OATD-02 (an ARG1/2 inhibitor), are approaching important clinical development milestones. In July 2023, the FDA accepted the company’s IND application for OATD-01, permitting the start of clinical studies in the United States. The Phase II trial in sarcoidosis is expected to commence in Q423; top-line results are expected in Q125. The company’s second clinical asset, OATD-02, began Phase I in solid tumour indications in Q123. In July 2023, Molecure secured (secondary) financing with a gross value of around PLN50m, which will be used to co-finance the company’s strategic plans for 2023–25.